| Keywords: |
treatment outcome; clinical trial; bevacizumab; fluorouracil; placebo; patient selection; unspecified side effect; clinical trials as topic; note; capecitabine; adjuvant therapy; cancer staging; colorectal cancer; adenocarcinoma; medical decision making; metastasis; antineoplastic combined chemotherapy protocols; patient assessment; neovascularization, pathologic; cetuximab; cancer therapy; irinotecan; panitumumab; colorectal neoplasms; antibodies, monoclonal; drug mechanism; heart infarction; folinic acid; oxaliplatin; deoxycytidine; angiogenesis inhibitors; digestive system perforation; wound healing impairment; organoplatinum compounds; leucovorin; drug use; cerebrovascular accident
|
